Compare Asana Inc. (ASAN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs 10X Genomics Inc — how do they compare? Asana Inc. trades at $8.97 (market cap $2.13B), while 10X Genomics Inc trades at $57.01 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 3.6× Asana Inc.'s market cap, and 10X Genomics Inc is trading nearer its 52-week high, Asana Inc. nearer its low. Which is the better fit depends on your goals.
| ASAN | TXG | |
|---|---|---|
Market Cap | $2.13B | $7.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $58.57 |
52-Week Low | $5.46 | $11.34 |
Enterprise Value | $1.96B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $8.96, down 2.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth continues, reaching $723.88M in 2025, while net losses persist at -$255.54M. Recent Q1 2026 earnings beat expectations, and the company secured FedRAMP authorization and acquired StackAI to enhance AI capabilities, signaling strategic growth initiatives.
The outlook hinges on Asana's path to profitability amid high competition; analyst consensus is mixed with a $10.33 price target. Key risks include sustained losses and competitive pressure from larger tech firms, but AI product adoption and government contracts offer potential upside if execution improves.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
